3Benner JS, Pollack MF, Smith TW. Association between short term effectiveness of statins and long term adherence to lipid lowering therapy[J]. An: J Health Syst Pharm, 2005,62 (14) 1468-1475.
4Guilmot JL, Diot E, Gruel Y. Contribution of platelet aggregation inhibitors in the prevention of complications of atherothrothrombosis[J]. Presse Med, 2000,29 (13) : 709 -716.
4Jeffrey S. Berger,Maria C. Roncaglioni,Fausto Avanzini,Ierta Pangrazzi,Gianni Tognoni,David L. Brown,崔艳丽（译）,赵秀丽（校）.阿斯匹林在男性和女性心血管事件一级预防中的应用——随机对照试验性别特异性汇总分析[J].美国医学会杂志（中文版）,2006,25(5):275-282. 被引量：40
6Xu G, Liu X, Zhu W, et al. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention [J]. Blood Coagul Fibrinolysis,2007,18(2) :193 -197.
7Uyttenboogaart M, Vroomen PC,Stewart RE, et al. Safety of routine Ⅳ thrombolysis between 3 and 4. 5 h after ischemic stroke [J]. J Neurol Sci,2007,254 ( 1 - 2 ) :28 - 32.
8Mattle HP, Arnold M, Georgiadis D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyper-dense middle cerebral artery sign [ J ]. Stroke ,2008,39 (2) :379 - 383.
9Yamaguchi T, Mori E, Minematsu K, et al. Alteplase at 0. 6 mg/kg for acute ischemic stroke within 3 hours of onset:Japan Alteplase Clinical Trial (J-ACT) [ J ]. Stroke,2006,37 (7) : 1810 - 1815.
4Chu,H.X.,Kim,H.A.,Lee,S.et al.Immune cell infiltration in malignant middle cerebral artery infarction:Comparison with transient cerebral ischemia[J].Journal of Cerebral Blood Flow and Metabolism:Official Journal of the International Society of Cerebral Blood Flow and\sMetabolism,2014,34(3):450-459.
